Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 14/20 | 0.62 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | IRS1 | P35568 | 1/20 | 0.48 |
| ▸ | GAB1 | Q13480 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8730165 | 0.87 | TBXA2R (0.70) | TBXA2R | |
| SCHEMBL8730117 | 0.87 | TBXA2R (0.61) | TBXA2RLMNAHTTSMN1; SMN2 | |
| SCHEMBL8734691 | 0.85 | TBXA2R (0.70) | TBXA2RALDH1A1 | |
| SCHEMBL8733559 | 0.84 | TBXA2R (0.54) | TBXA2RLMNAHTTSMN1; SMN2 | |
| SCHEMBL8731670 | 0.84 | TBXA2R (0.82) | TBXA2R | |
| SCHEMBL8733779 | 0.83 | TBXA2R (0.70) | TBXA2R | |
| SCHEMBL5673556 | 0.83 | TBXA2R (0.85) | TBXA2R | |
| SCHEMBL8730048 | 0.83 | TBXA2R (0.70) | TBXA2R | |
| SCHEMBL8734661 | 0.83 | TBXA2R (0.70) | TBXA2R | |
| SCHEMBL8728418 | 0.82 | TBXA2R (0.66) | TBXA2RLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5750524-A | ADMINISTERING AN SULFAMIDE SUBSTITUTED INDAN DERIVATIVE | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1998-05-12 | — | — | US | disclosed |
| EP-0773019-A1 | HYPERLIPEMIA REMEDY | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-14 | — | — | EP | disclosed |